Market Growth ALPCO operates in the infectious and gastroenterological diagnostics space with FDA-cleared Calprotectin Immunoturbidimetric Assay and GI biomarker solutions, indicating opportunities to cross-sell additional GI panels, automated systems, and companion diagnostics to labs expanding GI diagnostics capabilities.

Partnerships & OEM Recent and past partnerships with Dynex Technologies and Gold Standard Diagnostics suggest a receptiveness to collaborative automation and benchtop ELISA solutions, presenting a path to offer integrated automation, instrumentation, and reagent packages to existing ALPCO customers.

Global Expansion Global launches such as the European rollout of the Calprotectin assay imply growing international demand; sales teams can target international labs and distributors with scalable GI testing solutions and localized support, along with training and service packages.

Strategic Leadership New CEO appointment in 2023 and continued product launches indicate a forward-leaning strategic roadmap; leverage this momentum to position premium service contracts, portfolio add-ons, and early-access programs for customers wanting cutting-edge diagnostics.

Mid-Sized Focus Company size (51-200 employees) places ALPCO between niche specialists and larger CROs; target mid-sized clinical and research laboratories with comprehensive, user-friendly diagnostic solutions, automation-ready platforms, and scalable pricing models.